Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.

Autor: England E; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Rees DG; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Scott IC; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Carmen S; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Chan DTY; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Chaillan Huntington CE; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Houslay KF; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Erngren T; Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Penney M; Early Oncology DMPK, Oncology R&D, AstraZeneca, Cambridge, UK., Majithiya JB; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Rapley L; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Sims DA; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Hollins C; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Hinchy EC; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Strain MD; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Kemp BP; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Corkill DJ; Bioscience In Vivo, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., May RD; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Vousden KA; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Butler RJ; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Mustelin T; Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA., Vaughan TJ; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Lowe DC; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Colley C; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Cohen ES; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. suzanne.cohen@astrazeneca.com.

Publikováno v: Scientific reports [Sci Rep] 2023 Jun 17; Vol. 13 (1), pp. 9825. Date of Electronic Publication: 2023 Jun 17.

The P6-P2 region of serpins is critical for proteinase inhibition and complex stability.

Autor: Chaillan-Huntington CE; Department of Oral Medicine and Diagnostic Sciences, University of Illinois at Chicago, Chicago, Illinois 60612, USA., Gettins PG, Huntington JA, Patston PA

Publikováno v: Biochemistry [Biochemistry] 1997 Aug 05; Vol. 36 (31), pp. 9562-70.